X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Rapid Cutback of Intracranial Pressure By Injectable Peptide

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Default Eligibility Results In Better Clinical Trial Nods

    Researchers Develop Revolutionary Treatment In Bone Cancer

    Singapore Precision Drugs To Excel By Next-Gen Proteomics

    Temperature Stable TB Vaccine Gives Out Immune Response

    T Cells Are Fruitful In Thwarting-Off Chronic Infections

    Randomness Drives Tumour Cells Response To Chemotherapy

    mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Rapid Cutback of Intracranial Pressure By Injectable Peptide

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Default Eligibility Results In Better Clinical Trial Nods

    Researchers Develop Revolutionary Treatment In Bone Cancer

    Singapore Precision Drugs To Excel By Next-Gen Proteomics

    Temperature Stable TB Vaccine Gives Out Immune Response

    T Cells Are Fruitful In Thwarting-Off Chronic Infections

    Randomness Drives Tumour Cells Response To Chemotherapy

    mAbs And Therapeutic Proteins Potency Guidance Issued By FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Rapid Cutback of Intracranial Pressure By Injectable Peptide

Content Team by Content Team
16th March 2023
in Drug Development, News

It has come to light that patient with idiopathic intracranial hypertension- IIH can be treated with an injectable peptide used for type 2 diabetes. This has been found in a Phase II trial. As per the study’s latest findings, the brain pressure was reduced significantly in just about two and a half hours after an exenatide injection, which is a GLP-1 receptor agonist.

IIH happens to be a condition that goes on to raise the pressure in the brain, which is most likely due to a cerebrospinal fluid imbalance. One of the major risk factors for developing IIH is weight gain. The symptoms include chronic headaches, which can also lead to pressure on the optic nerve, resulting in blindness. This illness predominantly has an impact on women aged 25 to 36. Although this condition is rare, the scientists have highlighted that there has been a surge of 350% in these incidences over the last 10 years.

Apparently, there aren’t any licensed drugs as of now to treat IIH, and therefore, this result happens to be a major step forward for patients suffering from it, said Alex Sinclair, who happens to be the professor of neurology at the University of Birmingham’s Institute of Metabolism and Systems Research. He is the lead investigator of this study.

Across the 16 patients in the clinical trial, the subcutaneous injection, which was administered twice daily, went on to facilitate an average of 7.7 fewer days in a month when it came to headaches as compared to the baseline. This was in comparison to just 1.5 fewer days when it came to the placebo arm.

Of the seven patients who received the regular exenatide injection, a drop in the brain pressure was observed in both the short-term (i.e., 2.5 hours and 24 hours) and the long-term (a 12-week measurement).

While all the female participants of the trial were able to continue exenatide with some mild adverse effects, the treatment did cause nausea because of the twice-daily delivery of the drug through injection. Because of this, the drug has now been reformulated as Presendin. This once-a-week injection is designed to lower brain pressure within hours of administering it, with the dose lasting for a week.

The chair of the patient charity at IIH UK, Shelly Williamson, stated that they look forward to the next steps and see the drug being tested in two massive Phase III clinical trials. The IIH Advance is a Phase III clinical trial in adolescents that is run across the UK and sponsored by the University of Birmingham. The trial will go on to randomize patients with IIH so as to determine the safety as well as efficacy of Presendin against the placebo.

On the other hand, IIH EVOLVE happens to be an international Phase III clinical trial that will randomize 240 adult patients with newly diagnosed IIH and papilloedema so as to gauge the efficacy as well as safety when it comes to Presendin, which is administered once a week for 24 weeks. Apparently, the primary endpoint of IIH EVOLVE will analyse the efficacy of Presendin so as to reduce intracranial pressure for 24 weeks as compared to the placebo.

Keywords- Idiopathic Intracranial Hypertension, International Phase III Clinical Trial, GLP-1 Receptor Agonist, Randomize Patients With IIH, Drug Has Now Been Reformulated As Presendin.

 

Previous Post

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

Related Posts

Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Default Eligibility Results In Better Clinical Trial Nods

10th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
Drug Development

Singapore Precision Drugs To Excel By Next-Gen Proteomics

10th March 2023
Clinical Trials

Temperature Stable TB Vaccine Gives Out Immune Response

10th March 2023
News

T Cells Are Fruitful In Thwarting-Off Chronic Infections

10th March 2023

Latest News

Drug Development

Rapid Cutback of Intracranial Pressure By Injectable Peptide

16th March 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
News

Tumors Can Get Destroyed By Bacteria-Aid To Immune System

16th March 2023
News

Default Eligibility Results In Better Clinical Trial Nods

10th March 2023
News

Researchers Develop Revolutionary Treatment In Bone Cancer

10th March 2023
Drug Development

Singapore Precision Drugs To Excel By Next-Gen Proteomics

10th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In